Cerebral venous thrombosis (CVT) is a unique cause of stroke. Population-based studies demonstrate an incidence of clinically significant CVT of 1.3–1.5 per 100,000 per year. This may be an underestimated incidence, as these studies were not based on review of imaging and the often benign nature of this entity may lead to underdiagnoses. In the JNIS paper published by Cleaver et al., the authors describe their experience with endovascular treatment (EVT) in patients with cerebral venous sinus thrombosis in patients following COVID-19 vaccination.

CVT-related stroke primarily affects young adult and middle-aged patients. Although initially blamed for having a 50% mortality based on autopsy series, more recent prospective multinational studies (International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT)) have demonstrated a mortality rate of 8% in a cohort of 624 patients. A total of 75% of these patients were female and 13% had a poor outcome (death or dependence). The baseline risk factors for poor outcome included age >37 years (HR=2.0), male sex (HR=1.6), coma (HR=2.7), mental status disorder (HR=2.0), hemorrhage on admission computed tomography (CT) scan (HR=1.9), thrombosis of the deep cerebral venous system (HR=2.9), central nervous system infection (HR=3.3), and cancer (HR=2.9). Only 8% of these patients were >65 years of age, and had a poorer prognosis. Female predilection was lost in the elderly age group, with both sexes affected almost equally. Some 46% of these patients demonstrated infarct on CT/magnetic resonance imaging (MRI) while 39% of these patients demonstrated hemorrhage.

Traditionally, all major guidelines have recommended anticoagulation with heparin – preferentially low molecular weight heparin – as the standard treatment for CVT, regardless of the presence of an intracerebral hemorrhage (ICH). Heparin treatment is supposed to prevent growth or embolization of the existing thrombus, and facilitate recanalization. Patients with cerebral sinus thrombosis treated with anticoagulants (low molecular weight heparin followed by oral anticoagulation) had a favorable outcome more often than controls, although the difference was not statistically significant.

Hypercoagulability and CVT after COVID-19 infection and vaccination has been described, especially after vaccination with the adenovirus vector vaccine ChAdOx1 (Oxford/AstraZeneca), which is associated with very low platelets, antplatelet factor 4 antibodies and elevated d-dimer, leading to the designation of vaccine-induced thrombotic thrombocytopenia (VITT).

In a study of 95 patients with CVT, 70 of whom had VITT and 25 did not, primary outcome of death or dependency occurred more frequently in patients with VITT-associated CVT (47%) compared with the non-VITT control group (16%; P=0.0061). The median age of the VITT group (47 years) was lower than in the non-VITT group (57 years; P=0.0045). Patients with VITT-associated CVT had more thrombosed intracranial veins (three) than non-VITT patients (two) and more frequently had extracranial thrombosis (44%) compared with non-VITT patients (4%; P=0.0003). The adverse outcomes were less frequent in patients with VITT who received non-heparin anticoagulants (18/50 (36%) patients) compared with those who did not (15/20 (75%) patients; P=0.0031), and in those who received intravenous immunoglobulin (22/55 (40%) patients) compared with those who did not (11/15 (73%) patients; P=0.022). Treatment guidelines advocate not using heparin in patients with suspected VITT; instead treatment is focused on intravenous immunoglobulin and nonheparin anticoagulation.

EVT is advocated in patients with COVID-19 infection-related emergent large vessel occlusion (ELVO) and to treat patients with CVT. EVT for CVT aims to achieve rapid recanalization of the cerebral venous sinuses through local mechanical thrombectomy, thrombolytic drug administration, or a combination of both. These methods result in more rapid recanalization, by delivering the drug where needed, downstream from the cerebral venous infarcts which may be hemorrhagic, and increasing the surface area of the thrombus exposed to thrombolytics. This is usually advocated when clinical neurologic deterioration occurs despite anticoagulation treatment.

The European Stroke Organisation guidelines, however, do not include or provide a recommendation on EVT for CVT, whereas the American Heart Association guideline recommended considering EVT only in patients who deteriorate despite anticoagulant treatment. In a systematic review of mechanical thrombectomy in CVT, of 185 cases in 42 studies, 156 (84%) of patients had a good outcome and 22 died (12%). Some 10% of patients demonstrated new or increased periprocedural hemorrhage with a failure rate of 5%.

The TO-ACT (Thrombolysis or Anti-coagulation for Cerebral Venous Thrombosis) trial was designed to test the hypothesis that EVT in addition to standard medical care improves the clinical outcome of patients with severe CVT compared with standard medical care alone. Of 67 enrolled and randomized patients, 33 (49%) were randomized to EVT and standard medical therapy (intervention group) and 34 (51%) were randomized to receive guideline-based standard medical care (control group). The intervention consisted of mechanical thrombectomy, pharmacological thrombolysis, or a combination of both. The interventional treatment was made at the discretion of the interventionalist, although the maximum doses of pharmacological agents were specified in the trial protocol. Continuous infusion with a thrombolytic drug in the affected sinus was allowed after the initial procedure for a maximum of 72 hours. For mechanical thrombectomy, the use of devices was allowed at the discretion of the interventionalist. At the 12-month follow-up, 22 intervention patients (67%) had a modified Rankin score (mRS) of 0 to 1 compared with 23 control patients (68%) (relative risk ratio 0.99). EVT with standard medical care did not appear to improve functional outcome of patients with CVT, although mortality was not statistically significantly higher in the EVT group (12% vs 3%; P=0.20). The frequency of symptomatic ICH was also not statistically
significantly lower in the intervention group (3% vs 9%; P=0.61). The study included adult patients (aged ≥18 years) who had radiologically confirmed CVT with a high probability of poor outcome, defined as the presence of at least one of the following risk factors: mental status disorder, coma state (Glasgow Coma Scale score <9), ICH, or thrombosis of the deep cerebral venous system. Considering the difference in outcomes and pathogenesis, and a higher mortality rate in this subgroup, a case for EVT can be made in this specific subgroup of patients with CVT. Although enticing, the use of EVT in this subgroup is likely to be of limited clinical relevance broadly, considering the low rate of vaccination with this type of vaccine (Johnson & Johnson (JNJ) vaccine 16 million vs 172 million for Moderna and 263 million for the Pfizer vaccine).23 Given the relative infrequency of this complication, the low rate of vaccination of world populations using the JNJ vaccine, and the high relative costs of EVT, this is likely to remain a niche therapy to be used in the direst of circumstances, to be used if local neurointerventional expertise is available.

Whether the results of this study should open up the use of EVT to all patients with CVT is a large leap of faith, based on the negative results of the TO-ACT trial. Although a case for EVT could still be made, based on the heterogeneity of the study population and the lack of standardization of EVT therapy in this particular condition across numerous worldwide sites, the relative value of this technique still needs to be established in a well-designed, and perhaps larger, clinical trial under controlled conditions.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data sharing not applicable as no datasets generated and/or analyzed for this study. Not applicable.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/neurintsurg-2021-018516).

To cite Mahajan A, Hirsch JA. J Neurointerv Surg 2022;14:849–850. Accepted 30 January 2022 Published Online First 17 February 2022

http://dx.doi.org/10.1136/neurintsurg-2021-018238

J Neurointerv Surg 2022;14:849–850. doi:10.1136/neurintsurg-2021-018516

ORCID id Joshua A Hirsch http://orcid.org/0000-0002-9594-8798

REFERENCES